lactobacillus plantarum HFY15 + bifidobacterium animalis

This is a combination of two probiotic bacterial strains—Lactobacillus plantarum HFY15 and Bifidobacterium animalis—administered together as a live biotherapeutic product. Both are non-pathogenic, commensal bacteria found in the human gut and commonly used in dietary supplements for their potential health benefits. Lactobacillus plantarum (now also known as Lactiplantibacillus plantarum) is recognized for its ability to break down food, absorb nutrients, and inhibit pathogenic organisms[3]. Bifidobacterium animalis (including subspecies such as B. animalis subsp. lactis) similarly supports digestion and immune function[6][7]. When combined, these probiotics have demonstrated synergistic effects in preclinical models; specifically, they can modulate immune responses by increasing regulatory T cell populations (CD4+CD25+Foxp3+) and shifting cytokine profiles toward anti-inflammatory states[1]. Mechanistically, this combination has been shown to delay disease onset and reduce severity in experimental autoimmune encephalomyelitis (EAE), an established mouse model of multiple sclerosis. The effect is mediated through enhanced Treg differentiation via upregulation of Foxp3 and GATA3 transcription factors while inhibiting Th1/Th17 differentiation[1]. The primary indications under investigation include inflammatory diseases such as multiple sclerosis (preclinical/animal studies). Both strains are widely available individually or in various probiotic blends marketed for digestive health.

Other names

lactiplantibacillus plantarum HFY15 + bifidobacterium animalisl. plantarum HFY15 + b. animalis